yep sounds like we're basically in agreement. I'm going to throw...

yep sounds like we're basically in agreement.

I'm going to throw in a bit of speculation though, and bear in mind that this is the result of a bit of googling and no medical expertise. So take the following with a very large grain of salt.

The last line in the ann about FDA approval has a general comment about targeting "conditions where systemic LPS is believed to play a critical role". So when you google "systemic LPS" you get a bunch of links describing connections to neuroinflammation (eg Parkinson's disease).

Way back in the non-deal roadshow from March last year, the list of clinical programs includes a timeline for autism studies.

Now this is a world away from the NASH/ASH/NAFLD area. Is this idea of LPS/ neuroinflammation being linked still current or has it been discounted? Does the autism program have any momentum?

I don't want to go pushing a "magic pill" scenario but it interests me as to whether the idea of using IMM124 in neurological situations is vaguely plausible or not. My understanding is that the gut/brain thing is a trendy topic but I have no idea what the real hard science is and whether IMM124 is relevant.

But if HC is not for speculation then what is if for, that's what I say......